Knowledge hub

For the annual European Congress of Radiology meeting in Vienna, Oxipit has conducted a retrospective validation study from internal ChestEye Quality performance data at more than 10 pilot deployment institutions. The study concludes that 1 in 552 (0.18%) chest X-ray studies reported by a radiologist include clinically significant diagnostic mistakes. The vast majority - 78.46% - of the errors are missed findings of pulmonary nodules and lymphadenopathy.

Researchers in Finland released a preprint of a study on the application performance on real-world clinical data. In the study, the application analyzed 10.000 chest X-rays of Finnish primary health care patients. ChestLink software was able to identify normal studies with 99.8% sensitivity and and specificity of 36.4% with a minimal number of false negatives that would lead to effectively no compromise on patient safety and no critical findings missed by the software.

The companies conducted a joint pilot study, where Oxipit’s ChestEye Quality AI software is employed for improved pulmonary nodule detection. The software was deployed in two major primary care centers in Lithuania. With nearly 50.000 chest X-ray images analyzed over the course of 2021, ChestEye Quality helped to detect 82 additional clinically relevant nodule findings, potentially identifying additional early instances of lung cancer.

ChestLink is the first AI medical application to produce imaging study reports without any involvement from a human radiologist. This FAQ article explains 'everything ChestLink' in simple terms.

AI medical imaging application developer Oxipit was granted CE Class IIb certification for ChestLink autonomous AI imaging suite. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist. It is the first regulatory approved AI medical imaging application to perform diagnostics autonomously.

At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data.

Dr Naglis Ramanauskas is a researcher at Oxipit. Trained as a radiologist, he aims to use his first-hand clinical experience to maximize the added value of Oxipit medical imaging products. In this talk with Dr Ramanauskas we discuss how AI productization and workflow alignment are no less important than statistical model performance.

Prof Osmo Tervonen is a professor and a senior radiologist at Oulu University Hospital in Finland. He is also a partner in Parasmed - a Nairobi based medical device distributor, which provides access to emerging medical technologies to the countries in the East African region. In his interview with Oxipit, prof Tervonen shares his views on AI in healthcare and AI’s role in the field of value based medicine.

AI medical imaging company Oxipit appointed Dany Chammas as their new Chief Commercial Officer. With more than 15 years of experience in top tier medical imaging companies, Dany will join the Executive Team to increase Oxipit’s visibility and accelerate business growth.

In the last post we highlighted how AI medical imaging solutions can serve as ‘a second set of eyes’ reducing the risk of overlooked findings. Operating in near-real time, they can affect patient treatment decisions, mitigating the risk of missed potentially life-threatening pathologies.